Search clinical trials for: BGB-43395

Total 231 results

MapKure, LLC

Recruiting

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Solid Tumor | B-Raf Mutation-Related Tumors

United States, Australia
Novartis Pharmaceuticals

Withdrawn

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (AdvanTIG-211)

Triple Negative Breast Cancer
BeiGene

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China, Taiwan, Australia, United States
BeiGene

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Healthy Volunteers

United States
BeiGene

Completed

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China, Korea, Republic of, United States
BeiGene

Completed

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

HER2-negative Breast Cancer

China
BeiGene

Completed

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma

China, Taiwan
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
Peter MacCallum Cancer Centre, Australia

Completed

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO)

Adenoid Cystic Carcinoma | Colorectal Cancer

Australia
BeiGene

Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | B-cell Malignancy

United States, Spain, Italy, Australia, France, Korea, Republic of, United Kingdom, Canada, Brazil, Georgia, Sweden, Germany, Moldova, Republic of
BeiGene

Active, not recruiting

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced and Metastatic Solid Tumors

China, Taiwan, United States, Australia
BeiGene

Completed

AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of, Spain, China, Thailand, Taiwan, France
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China, Australia
Sun Yat-sen University

Recruiting

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Metastatic Castration-resistant Prostate Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer (NEXUS-2)

Esophagus Cancer

China
BeiGene

Completed

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency & Healthy Subjects

United States
BeiGene

Recruiting

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

United States, Spain, Australia, New Zealand, Korea, Republic of, China, Brazil, Netherlands, United Kingdom, Canada, Poland, Puerto Rico
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
M.D. Anderson Cancer Center

Recruiting

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
BeiGene

Recruiting

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China, Georgia, Moldova, Republic of
BeiGene

Recruiting

Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

United States, Australia, France, China, Spain, United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BeiGene

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 Mutation

United States
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
BeiGene

Recruiting

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
National Taiwan University Hospital
National Taiwan University Hospital, Yun-Lin Branch

Recruiting

Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Taiwan
German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
Zhongda Hospital

Recruiting

Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
BeiGene

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Australia, Korea, Republic of, United States
Qilu Hospital of Shandong University

Not yet recruiting

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer (RCTS)

HER2-positive Gastric Cancer

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Lung Cancer
BeiGene USA, Inc.

Completed

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Brain and Central Nervous System Tumors

United States, Netherlands, Switzerland
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

MCL
BeiGene

Recruiting

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

B-cell Malignancies

China, Italy, United States, Spain, United Kingdom, Poland, Czechia, Netherlands, Greece, France, Sweden, Korea, Republic of, Turkey
BeiGene
Lymphoma Study Association

Active, not recruiting

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (TIRHOL)

Classical Hodgkin Lymphoma

United States, Australia, France, Belgium, Puerto Rico
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Chemotherapy | Gastric Cancer Stage IV | Tislelizumab | First-line

China
Celgene
BeiGene

Terminated

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Japan, China, Canada, United Kingdom, Belgium, Singapore, Korea, Republic of, Netherlands, France, Romania, Greece, Germany, Taiwan, Finland, Italy, Poland, Hungary, Ireland, Portugal, New Zealand, Russian Federation
Hutchmed
BeiGene

Active, not recruiting

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors | Metastatic Solid Tumor | Anaplastic Thyroid Cancer

United States
Northwell Health

Completed

BioGene Bank Cohort Study for Approved Research Requests (BGB)

Healthy | Chronic Disease

United States
BeiGene

Active, not recruiting

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Resectable Esophageal Squamous Cell Carcinoma

China
UNICANCER

Recruiting

Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions (HESTIA)

Hepatocellular Carcinoma by BCLC Stage

France
BeiGene

Not yet recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor | Advanced Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Alpha-fetoprotein (AFP)-Producing Gastric Cancer | Extragonadal Yolk Sac Tumors | Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
BeiGene

Active, not recruiting

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Colorectal Cancer

China
BeiGene

Completed

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Advanced Solid Tumors

China
BeiGene

Recruiting

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Mature B-Cell Malignancies

United States, Italy, Australia, New Zealand, Spain, United Kingdom, Germany
BeiGene

Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Melanoma | Renal Cell Carcinoma | Urothelial Carcinoma

China
BeiGene

Not yet recruiting

Phase 1 First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor
BeiGene

Completed

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Cervical Cancer

Korea, Republic of, Taiwan, China, Thailand, Poland, Bulgaria, Russian Federation, Ukraine
HiFiBiO Therapeutics

Recruiting

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Testicular Germ Cell Tumor | Gastric Cancer | Non Small Cell Lung Cancer | Mesothelioma | Head and Neck Squamous Cell Carcinoma

United States, Spain
Sun Yat-sen University
Wuzhou Red Cross Hospital; Hunan Cancer Hospital; Cancer Hospital of Guizhou... and other collaborators

Active, not recruiting

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China

Search clinical trials for: BGB-43395

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations